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Abstract: Patients with chronic non-cancer pain (CNCP) often use opioids for long periods of time.
This may lead to opioid use disorder (OUD) and psychiatric symptoms: mainly depression and
anxiety. The current study investigated the effect of buprenorphine/naloxone (BuNa) rotation on
opioid misuse, craving, psychiatric symptoms and pain in patients with CNCP and OUD. Forty-three
participants with CNCP and OUD were converted from a full mu-receptor agonist opioid (mean
morphine equivalent dose: 328.3 mg) to BuNa, in an inpatient setting. Opioid misuse, craving,
co-occurring psychiatric symptoms, and pain perception were determined at baseline and after
a two-month follow-up, using the following self-report questionnaires: Current Opioid Misuse
Measurement (COMM), Visual Analog Scale (VAS-craving and VAS-pain) and Depression, Anxiety
and Stress Scale (DASS), respectively. VAS-craving and VAS-pain were also determined immediately
after conversion. A total of 37 participants completed the protocol. The mean COMM decreased from
17.1 to 6.7 (F = 36.5; p < 0.000), the mean VAS-craving decreased from 39.3 to 5.3 (−86.6%; F = 26.5,
p < 0.000), the mean DASS decreased from 12.1 to 6.6 (F = 56.3, p < 0.000), and the mean VAS-pain
decreased from 51.3 to 37.2 (−27.4%, F = 3.3; p = 0.043). Rotation to BuNa in patients with CNCP and
OUD was accompanied by reductions in (i) opioid misuse, (ii) opioid craving, (iii) the severity of
co-occurring psychiatric symptoms, and (iv) self-reported pain. BuNa as opioid agonist treatment
may therefore be a beneficial strategy in CNCP patients with OUD. The limited sample size and the
observational nature of this study underline the need for the replication of the current findings in
large-scale, controlled studies.
Keywords: opioid use disorder; chronic non-cancer pain; buprenorphine/naloxone; opioid misuse;
craving; depression; anxiety; stress; pain
1. Introduction
Worldwide there has been a marked increase in opioid prescriptions for chronic non-
cancer pain (CNCP) since the mid-1990s [1,2]. Particularly, the United States (US) faced a
large increase in opioid prescriptions, leading to prescription opioid use in 17.4% of the
general population in the US, in 2017 [3].
Despite the effectiveness of opioids as analgesics in severe acute pain, there is limited
evidence for the long-term analgesic effects of opioids [4,5]. In addition, long-term opioid
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use is associated with numerous adverse effects, including constipation, respiratory de-
pressions, sedation, reduced concentration, opioid use disorder (OUD) and opioid-related
mortality [6–9]. In addition, both chronic pain and long-term opioid use are associated with
the development of psychiatric comorbidities, including depression and anxiety, and re-
duced quality of life [10–12]. Physical dependence may develop rapidly after the initiation
of opioid use, leading to a tolerance for the analgesic effects of opioids, and withdrawal
when opioids are not taken. Furthermore, both opioid-induced hyperalgesia, characterized
by an increased sensitivity to pain induced by full mu-receptor agonists, and tolerance
for the analgesic effects of full mu-opioid receptor agonists, may contribute to a desire for
increasing opioid doses [13,14]. Patients may subsequently develop OUD, including the
continued use despite many negative health consequences, the loss of control of opioid use,
and cravings for opioids [15]. A systematic review found a point-prevalence of addiction
of 8–12% among patients with CNCP [16]. In addition, meta-analysis found a pooled
incidence of OUD in approximately 4.7% of patients using opioids for pain relief [17].
The combination of prescription OUD and CNCP poses a clinical challenge since,
on the one hand OUD requires the tapering of opioids, while on the other hand this
might temporarily increase pain and craving, hindering the successful detoxification of
opioids [18–21]. An alternative strategy for these patients might be opioid agonist treatment
(OAT) with a long-acting mu-opioid receptor agonist, since long-acting opioids might not
only stabilize opioid use, but simultaneously provide pain relief. Indeed, some studies
investigated the potential of methadone as an OAT in patients with prescription OUD and
CNCP, showing long-lasting improvement in pain control [22–24].
Buprenorphine OAT, optionally provided as a combination therapy with naloxone,
might be of specific interest for the treatment of patients with prescription OUD and
co-occurring CNCP, given its pharmacological profile [19,25]. Buprenorphine is a high-
affinity partial mu-opioid receptor agonist. Several studies suggest that buprenorphine
has similar equi-analgesic properties as full mu-opioid receptor agonists, like morphine
and transdermal fentanyl [26]. Studies on the effectiveness of buprenorphine rotation in
patients with CNCP and OUD suggested a positive effect on pain [23,27–31]. However,
these studies had a small sample size [23,31], were retrospective in nature [27,28,30], or
participants could self-administer additional oxycodone [29]. Additionally, buprenorphine
has a lower risk of respiratory depression, sedation and overdose [32,33]. Furthermore,
the dissociation rate of buprenorphine is slow, resulting in a long duration of action [32].
OAT with buprenorphine, commonly taken in combination with naltrexone (BuNa), has
repeatedly been associated with a decrease in craving over time in patients with OUD
without comorbid CNCP [34–39]. To our knowledge, only one study investigated the effects
of BuNa on craving in patients with iatrogenic OUD and co-morbid CNCP [23]. However,
this study had a small sample size (n = 19) and did not distinguish between the conversion
to methadone or BuNa. Finally, buprenorphine is a full kappa-opioid receptor antagonist,
which has been associated with antidepressant and anxiolytic effects [40–43]. In line with
this, there is an indication that buprenorphine has anti-depressant abilities [44–46]. These
effects have also been found in patients with OUD [47–51] and patients with CNCP [23].
Since the effects of BuNa OAT on opioid misuse, craving and psychiatric outcomes
have hardly been studied in CNCP patients with co-occurring OUD, the aim of the current
study was to explore the effectiveness of BuNa in patients with CNCP and OUD. The
primary objective was to study the effectiveness of BuNa in reducing opioid misuse and
craving. Secondary objectives included exploring the effects of BuNa on the severity of
co-occurring psychiatric symptoms and self-reported pain. Specifically, we tested the
hypotheses that opioid rotation to BuNa: (i) reduced current opioid misuse, (ii) reduced
opioid craving, (iii) improved psychiatric symptoms, and (iv) reduced self-reported pain.
J. Clin. Med. 2021, 10, 3727 3 of 13
2. Materials and Methods
2.1. Design
In this prospective, open-label, observational study, patients with CNCP and OUD
were rotated in an inpatient setting from their full mu-opioid receptor agonist to BuNa.
The regional medical ethical board approved this study (2015–1551) and all participants
gave written informed consent.
2.2. Participants
Participants (n = 43) with CNCP, who fulfilled criteria of chronic pain syndrome (longer
than 6 months) and had a co-occurring prescription OUD according to Diagnostic and
Statistical Manual of Mental Disorders 5 (DSM-5) [52,53], were referred to the Department
of Psychiatry of the Radboud University Medical Center (UMC) by their pain specialist or
general practitioner. The participants were volunteers seeking treatment for their OUD
and their admission was solely aimed at the BuNa rotation. Besides CNCP and OUD,
other inclusion criteria were: aged between 18–65 years, used opioids for at least one year
and an oral morphine equivalent (OME) dose exceeding 90 mg per day. Participants with
contraindications for BuNa (i.e., severe respiratory insufficiency, hepatic insufficiency)
and severe acute psychiatric comorbidity (e.g., acute psychosis, acute mania or severe
depression with suicidal ideation), were excluded. The participants were screened for
severe acute psychiatry at the outpatient Department of Dsychiatry at Radboud UMC,
based on clincal judgement by a trained physician assistant and experienced addiction
psychiatrist. None of the referred participants met the exclusion criteria. Data were collected
between 2017–2019.
2.3. Intervention
The rotation from full agonist opioids to BuNa took place in an inpatient Medical
Psychiatric Unit. In the first week of admission, long-acting morphine mimetics (e.g., fen-
tanyl and oxycodone), if used, were switched to dose-equivalent, short-acting oxycodone.
On the first morning of the consecutive week all short-acting oxycodone was stopped.
After complaints of withdrawal arose, guided by the objective withdrawal scale (OOS)
and subjective withdrawal scale (SOS) [54], the first dose of BuNa was given. Participants
started with 4/1 mg BuNa. Hereafter, the BuNa dose was subsequently titrated with
2/0.5 mg per 4 hours, based on subjective and objective withdrawal scores and pain per-
ception, to a maximum of 24/6 mg BuNa on day 1. The next day, participants received the
entire dose of the first day, divided in maximum three dosages, with additional BuNa if
needed. Hereafter, the BuNa dose was, similar to the previous day, titrated to a maximum
of 36/9 mg per day. The final dose scheme was determined in seven days and the partici-
pants stayed on this scheme until the follow-up after two months, unless dose adaptations
were necessary, e.g., due to severe side effects. Additional medication was prescribed as
needed to counteract withdrawal symptoms (clonidine, metoclopramide, and loperamide)
and pain (paracetamol, ibuprofen), in line with Dutch detoxification guidelines and the
guidelines of the American Society of Addiction Medicine [54,55]. In addition, during the
inpatient setting, the participants could participate in daily activities, consisting of routine
clinical care, offered to all patients admitted to our psychiatric unit, including a morning
opening meeting, a daily walk through the park and creative activities. After discharge, no
additional treatments or changes regarding medication were allowed.
2.4. Instruments
Socio-demographic data (sex, age, ethnicity, marital status, years of education, and
employment status) were collected on admission, as well as some baseline clinical data
(kind of opioid used, years of opioid used, OME, use non-opioid analgesics, other comedi-
cation, use of other psychoactive substances, pain type, and psychiatric history). Screening
for current psychiatric disorders was performed using the Mini International Neuropsychi-
atric Interview (MINI-Plus) [56,57] by trained clinicians. The MINI-plus was a structured
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and standardized diagnostic interview used to determine the most common psychiatric
disorders according to axis I DSM-IV-TR and the International Classification of Diseases
and Related Health Problems (ICD-10) [56–58]. It is widely used both clinically and in
research, and has been well-validated [56,57].
2.5. Opioid Misuse
Opioid misuse was assessed using the Current Opioid Misuse Measure (COMM) [59–61].
This was a self-report measure of aberrant opioid use in the past month. The COMM
consisted of 17 items and was created to monitor potential opioid misuse during opioid
treatment. All items were scored between 0 and 4, and subsequently summed into a total
score. Total scores above 9 were considered positive for opioid misuse. It was shown to be
a reliable and valid instrument to detect opioid misuse in CNCP patients [60].
Furthermore, opioid craving was assessed as an index of opioid misuse severity, using
a visual analog scale (VAS-craving). The VAS-craving was a quantitative measurement
where the participant quantifies their current state of craving by marking a point on a scale
form 0–100, with 0 as no craving at all and 100 as the most severe craving imaginable [62].
VAS-craving measurement was commonly used in addiction medicine to monitor craving
severity [62].
2.6. Psychiatric Symptoms
Psychiatric symptom severity was assessed using the Depression, Anxiety and Stress
Scale (DASS) [63]. The DASS is a 42-item self-administered questionnaire designed to
measure the severity of symptoms of depression, anxiety, and stress. Items are scored
on a 4-point Likert scale. For each subscale (depression, anxiety and stress) a total score
is computed by summing all individual items within that category. In addition, a DASS
total score is calculated. Finally, a categorical score was calculated per subscale with five
levels (normal, mild, moderate, severe, and extremely severe). The DASS had excellent
psychometric properties, with high reliability and validity [64].
2.7. Pain Assessment
Self-reported pain was measured using a visual analog scale (VAS-pain). Similar to
the VAS-craving, the VAS-pain was assessed on a horizontal line, of which the left end
of the scale represented “no pain” and the right end “the most severe pain imaginable”.
Participants quantified their current pain intensity by marking a point (from 0 to 100) on
the line [65]. The VAS-pain was validated for CNCP patients, showing similar sensitivity
compared with the often-used numeric rating scale (NRS) [66].
2.8. Procedure
After written informed consent, participants were planned for admission for opioid
rotation to BuNa. Baseline measurements (T0) of COMM, VAS-craving, DASS, VAS-pain,
OOS/SOS, and MINI-Plus were taken on the second day of admission, prior to any change
in opioid use. During the rotation procedure, the measurements (OOS/SOS, VAS-craving
and VAS-pain) were taken up to six times a day to facilitate dose titration of BuNa. Only
the last measurement of the VAS-craving and VAS-pain before discharge (T1) was analyzed,
in order to avoid state-dependent effects of the rotation on outcome measures. Two months
post discharge follow-up measurements were performed (T2), including COMM, VAS-
craving, DASS, and VAS-pain.
2.9. Statistical Analysis
In order to test our hypothesis, a per protocol analysis was used, given the small
sample size and naturalistic explorative study design. Participants who still used BuNa
at follow-up were considered completers. Descriptive data for continuous variables were
presented as means and standard deviation (SD). Descriptive data for categorical variables
were summarized by frequency and percentage. To answer our primary question, a
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univariate mixed model was performed with COMM scores as dependent variable, and
time as a fixed factor (two levels). Subsequently, additional univariate mixed-model
analyses were used to explore the effect of rotation to BuNa on craving (VAS-craving)
and pain severity (VAS-pain), with time as a fixed factor with three levels. Finally, a
multivariate mixed-model analysis was used to test the effects of BuNa rotation on the
severity of psychological symptoms (DASS-depression, DASS-anxiety, and DASS-stress
scores), with subscale (three levels) and time (two levels) as fixed factors. For all the mixed
models, compound symmetry was used as covariance type. All statistical tests were carried
out at the 0.05 level of significance using SPSS v.25 (IBM Corp, Armonk, NY, USA).
3. Results
Thirty-seven of the 43 included participants finished the rotation and were included
in the data analysis. Of the six participants who dropped out of the study, four were
set back to their previous opioids due to inadequate analgesia, one was switched to
buprenorphine instead of BuNa because of its bad taste, and one was lost to follow-up
(Figure 1). As can be seen in Supplementary Table S1, the mean OME at baseline was higher
in dropouts (593.3 ± 381.2) than in participants who completed the trial (328.3 ± 411.0;
p = 0.015). No other significant differences were found between dropouts and completers
(see Supplementary Table S1).
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Figure 1. Consort flow chart of the study.
Table 1 shows demographical variables (gender, age, race, years of education, marital
status and employment status). In addition, Supplementary Table S2 shows the psychiatric
morbidity, as assessed with the MINI-plus, at baseline. The mean age of the participants
was 47.5 years (±10.9) and 23 were male (62.2%). The mean OME at baseline was 328.3 mg
(±411.0), the mean duration of the prescription opioids was 5.6 years (±3.8), and the mean
daily dose of BuNa at discharge was 19.6 mg/4.9 mg (±8.2; ±2.1). The mean dose of BuNa
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at follow-up was 18.3 mg/4.6 mg (±9.9; ±2.5) per day. The main results of the descriptive
statistics and the statistical analyses are listed in Table 2.
Primary outcomes:
Table 1. Participants characteristics.



































Living with a partner; ‡ highest achieved degree of education (low: no education, pre-primary, primary, lower
secondary education, compulsory education, and initial vocational education; middle: upper secondary general
education, basic vocational education, secondary vocational education, and post-secondary education; high: spe-
cialized vocational education, university/college education, and doctorate and equivalent degrees); † Percentage
employed; § Amount of participants answering “yes” on substance use over the past 30 days; ‡‡ Main cause of
the chronic pain; †† Amount of participants taking these types of medication.
After rotation from opioids to BuNa, opioid misuse, as indexed by the mean COMM
score, decreased from 17.1 (SE = 1.40) at baseline, to 6.7 (SE = 1.45) at follow-up (F = 47.8;
p < 0.000). Furthermore, the number of participants with current opioid misuse (COMM> 9)
also decreased (pre: n = 29, 78.4%; post: n = 9, 24.3%; Chi-square = 19.2, p < 0.000). After
rotation to BuNa, craving levels reduced over time from 39.3 (SE = 4.23) at baseline, to 21.6
(SE = 4.34) after rotation and 5.3 (SE = 4.34) at follow-up (F = 26.4, p < 0.000). Post hoc
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analyses showed a decrease in craving levels from baseline to the final day of admission
(T0-T1: p < 0.000), and from baseline to follow-up (T0–T2: p < 0.000).
Table 2. Mean values of the dependent variables, combined with the corresponding p- and F-values.
Baseline; Mean
(±SE; 95% CI; Z-Score)
Discharge; Mean
(±SE; 95% CI; Z-Score)
Follow-up; Mean
(±SE; 95% CI; Z-Score) F-Value (df) p-Value
COMM 17.1 ± 1.40 (14.3–19.9; 0.504) - 6.7 ± 1.45 (3.8–9.6; −0.539) 36.50 (35.61) 0.000 *
VAS-craving 39.3 ± 4.23 (30.5–48.2; 0.590) 21.4 ± 4.34 (12.7–30.0; −0.016) 5.3 ± 4.34 (−3.4–13.9; −0.557) 26.42 (70.75) 0.000 *
DASS 12.1 ± 1.17 (9.8–14.5; 0.296) - 6.6 ± 1.19 (4.2–9.0; −0.341) 56.32(173.49) 0.000 *
VAS-pain 51.3 ± 4.53 (41.6–59.6; 0.267) 41.7 ± 4.42 (33.0–50.5; −0.057) 37.2 ± 4.42 (28.5–46.0; −0.222) 3.28 (70.11) 0.044 *
SE, standard error; CI, confidence interval; VAS, visual analog scale; COMM, current opioid misuse measurement; DASS, depression
anxiety stress scale; * p-value considered statistically significant (p < 0.05).
Secondary outcomes:
The severity of psychological symptoms on the DASS declined from baseline to follow-
up (F = 56.3; p < 0.000). Post hoc analyses showed a decrease in all the subscales of the
DASS (depression: F = 13.9; p = 0.001, anxiety: F = 23.6; p < 0.000, and stress: F = 14.1;
p = 0.001). Lastly, self-reported pain on the VAS-pain reduced from 51.3 at baseline to 37.2
at follow-up (27.5% decrease; F = 3.28; p = 0.044). Post hoc analysis showed that this was
mainly driven by an improvement in self-reported pain from baseline to follow-up (T0–T2:
p = 0.013).
4. Discussion
The present study investigated the effects of rotation from full mu-opioid recep-
tor agonists to BuNa, in patients with CNCP and OUD, on (i) current opioid misuse,
(ii) opioid craving, (iii) psychiatric symptoms, and (iv) self-reported pain. Thirty-seven of
the 43 participants finished the trial. Patients dropping out was mainly due to the inad-
equate pain control of BuNa (four out of six participants). As hypothesized, the opioid
rotation to BuNa reduced current opioid misuse and opioid craving, and improved psychi-
atric symptoms and self-reported pain. This suggests that opioid rotation to BuNa could
have beneficial effects in patients with CNCP and OUD.
Our findings are in compliance with previous research, suggesting that buprenor-
phine (with or without naloxone) reduces opioid misuse and craving in people with
OUD [23,34–39,67,68]. To our knowledge, only one study explored the effects of BuNa on
craving in patients with CNCP and OUD, showing a significant reduction of approximately
45 points on the VAS-craving scale [23], in line with the observed reduction in craving
observed in the current study. However, it should be noted that this previous study (i) had
a smaller study population (n = 19), (ii) with participants showing higher baseline craving
and (iii) could not distinguish between methadone and BuNa rotation. Furthermore, it
should be noted that about one fourth of participants still exceeded the cut-off value for
opioid misuse on the COMM at follow-up. This may indicate that after BuNa OAT some
patients may still misuse opioids. Future studies should address how to support these pa-
tients in gaining control over their opioid use. In addition, future research might consider a
broader assessment of opioid misuse. For instance, using biomarkers for the use of opioids
(urine testing), or DSM-5 criteria for OUD.
A possible explanation for the observed reduced misuse and craving of opioids after
rotation to BuNa might be due to the slower dissociation rate of buprenorphine, compared
to most full mu-opioid receptor agonists [32]. Furthermore, it has been suggested that
the partial agonism of buprenorphine in the mu-opioid receptor might cause less severe
withdrawal symptoms [69]. Since the naloxone component in BuNa has limited availability
in the central nervous system due to its first-pass effect, it is unlikely that the current
sublingual administration of naloxone contributed to the observed effects on craving [70].
However, any contributing central effects of naloxone cannot be fully ruled out.
The beneficial effects of rotation to BuNa on depression, anxiety and stress, as observed
in the current study, are also in line with previous research, showing antidepressant proper-
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ties of buprenorphine in patients with depression [45,51], in patients with OUD [45,47–50],
and in patients with OUD and CNCP [23]. It has been hypothesized that the kappa-
antagonism of buprenorphine might contribute to its antidepressant and stress-reducing
effects [71,72]. Indeed, the brain kappa-opioid receptor system has been linked with several
psychological symptoms, including depression and anxiety, and stress-related symptoms
in addictive disorders [73]. Furthermore, the anti-depressant and stress-reducing effects of
kappa-antagonists have also been observed in several animal studies [74,75]. In addition,
the discontinuation of full mu-opioid receptor agonists might have contributed to the
observed beneficial effects of BuNa rotation on mood symptoms. Indeed, full-mu receptor
agonists have been shown to have depressogenic properties [76–78]. The present study also
supports previous observations of BuNa as potentially beneficial for pain management in
CNCP patients with OUD. The reduction in pain intensity observed here (VAS -13 points on
average), is comparable with previous studies on the analgesic properties of buprenorphine
in CNCP patients with OUD (change in VAS ranging between −8 and −45) [23,30,31] and
in CNCP patients without OUD (change in VAS ranging between −23 and −37) [27]. It has
been hypothesized that the partial mu-opioid agonism and/or kappa-opioid antagonism
might reduce pain perception, due to a reduction of opioid-induced hyperalgesia [79,80].
The chronic use of full mu-opioid receptor agonists has been shown to cause hyperalgesia,
associated with increased sensitization of the central nervous system for pain stimuli,
resulting in lower pain thresholds and higher pain perception [13,14]. Reductions of opioid-
induced hyperalgesia after BuNa rotation may thus improve analgesia in CNCP patients
previously treated with full mu-opioid receptor agonists. However, due to the unreliable
OME conversion rates of BuNa, it cannot be ruled out that participants used a higher OME
after switching to BuNa. This may have contributed to the observed overall reduction in
pain severity.
It should be mentioned that, since four patients dropped out due to inadequate
analgesia, the analgesic effects of BuNa rotation may be overestimated in the current study.
In addition, participants who dropped out of the study showed higher baseline OME levels
in comparison with the analyzed participants. This may indicate that participants with a
higher OME at baseline are more likely to fail the conversion to BuNa. As can be seen in
Supplementary Table S1, those who dropped out did also have non-significant (i) higher
baseline craving levels, (ii) a younger age, and (iii) a higher baseline VAS-pain. Future
studies should further explore which patients are most likely to benefit from rotation to
BuNa, to facilitate patient–treatment matching.
The current findings should be interpreted in the light of several study limitations.
Due to the relatively small study population (n = 37) and observational design, general-
ization of the study results is limited and prevents drawing firm conclusions regarding
the effectivity of BuNa as OAT for patients with CNCP and OUD. Furthermore, with a
follow-up period of two months, our study did not investigate the long-term potential
of BuNa. Future randomized studies, with a larger study population, longer follow-up
period and a control group, are necessary to confirm our findings. In addition, our study
population consisted of mainly males (62.2%) and patients with nociceptive pain (54.1%).
Future studies should evaluate whether our findings are also apply to females and patients
with non-nociceptive pain.
It should be noted that opioids should preferably be discontinued in patients with
CNCP. Some studies suggest that opioid tapering might be beneficial in CNCP patients [81].
In methadone-rotated participants, success rates were about 28% [82]. Though this was not
the aim of the current study, it was highly relevant to investigate the tapering of BuNa in
patients with CNCP and OUD.
Finally, future research should also explore the beneficial effects of non-pharmacological
interventions in patients with CNCP and OUD, for instance in addition to BuNa rotation.
Cognitive Behavioral Therapy and Mindfulness are effective in reducing pain [83–85]
and addictive behaviors, including OUD [86]. Therefore, additional psychotherapy may
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increase the effectiveness of rotation from full agonist opioids to BuNa in patients with
CNCP and OUD and facilitate tapering BuNa after the rotation process.
In conclusion, this prospective observational study showed that the rotation from
full mu-opioid receptor agonists to BuNa had beneficial effects on opioid misuse, opioid
craving, the severity of co-occurring psychiatric symptoms, and the pain perception of
patients with CNCP and OUD. These findings suggested that BuNa rotation might be
a valuable strategy in CNCP patients with OUD. Future studies should replicate these
findings, and explore which patients benefit the most from rotation to BuNa, as 14% of our
participants dropped out of the trial, mainly due to inadequate analgesia.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/jcm10163727/s1, Table S1: Differences in mean between analyzed participants (n = 37) and
drop-outs (n = 6); Table S2: Baseline psychiatric comorbidity as defined with the Mini International
Neuropsychiatric Interview (MINI-plus).
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